Growth & Leadership Quibim is expanding globally with a new Chief Business Officer appointed in mid-2026, signaling aggressive scale in life sciences partnerships and international commercial reach. This presents an opening to position advanced imaging AI collaborations and enterprise deployments with global pharma, CROs, and large health systems.

Strategic Partnerships Recent collaborations with Aidoc and NVIDIA MONAI, plus a Blackford partnership to integrate QP-Prostate, indicate a proven channel strategy and readiness for co‑selling AI imaging solutions. Opportunities exist to propose joint solutions that leverage existing partner ecosystems and broaden hospital and clinic adoption.

AI‑Driven Offerings Quibim focuses on AI-powered imaging biomarkers across MRI, CT, and PET with products like AI-QUAL for prostate MRI. This positions Quibim to target precision medicine initiatives, radiology departments pursuing AI quality assurance, and institutions requiring standardized, regulator-ready imaging analytics.

Invested & Growing With a Series A funding of $50M led by Asabys and Buenavista and a total funding level of $70M, Quibim has capital to scale product development, clinical validation, and sales efforts. Sales plans can emphasize faster time-to-value and expanded clinical evidence to support large-scale deployments.

Scale‑Ready Use Cases Quibim’s QP-Prostate platform and automated image quality assessment align with growing demand for reproducible imaging workflows and standardized biomarkers. Targeted opportunities include health systems implementing AI-ready radiology pipelines, tumor boards requiring reliable imaging biomarkers, and payer-facing value demonstrations.